Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gene Expression Clear all
Completed Phase 3 Interventional Results available

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

NCT04296890
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
34
States / cities
Phoenix, Arizona • Duarte, California • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Jul 22, 2026, 2:08 PM EDT
Active, not recruiting Not applicable Interventional

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

NCT04396808
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher, Prolaris, Oncotype Dx Genomic Prostate Score (GPS), Standard of care (askMUSIC score)
Device · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
8
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression

NCT01030913
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
1,248 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2023
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

NCT00019825
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
Interventions
decitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Jul 22, 2026, 2:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Skin Aging: Clinical Parameters and Gene Expression Profiling

NCT01451476
View directory record Official record
Conditions
Ageing
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Jul 22, 2026, 2:08 PM EDT
Completed No phase listed Observational

Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer

NCT00550628
View directory record Official record
Conditions
Colorectal Cancer, Neoplasm of Uncertain Malignant Potential
Interventions
DNA methylation analysis, fluorescence in situ hybridization, gene expression analysis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method, biopsy, therapeutic conventional surgery, fludeoxyglucose F 18
Genetic · Other · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
15 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Jul 22, 2026, 2:08 PM EDT
Recruiting No phase listed Observational

GRoup A StrePtococcus

NCT01558804
View directory record Official record
Conditions
Streptococcal Pharyngitis
Interventions
Identifying group A strep carriers
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
5 Years to 15 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Completed No phase listed Observational

Transient Receptor Potential Vanilloid One (TRPV1) Receptor Expression in Children With Retrosternal Pain

NCT00677378
View directory record Official record
Conditions
Epigastric Pain, Retrosternal Pain, Esophagitis, Gastrointestinal Symptoms
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Not applicable Interventional

Gene Expression in Cumulus Cells to Predict Pregnancy

NCT01732900
View directory record Official record
Conditions
Infertility
Interventions
Morphology, GemART assay
Other
Lead sponsor
Gema Diagnostics
Industry
Eligibility
21 Years to 39 Years · Female only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Oak Brook, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2014 · Synced Jul 22, 2026, 2:08 PM EDT
Recruiting No phase listed Observational

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

NCT03053193
View directory record Official record
Conditions
Breast Cancer
Interventions
MammaPrint, BluePrint, and Full-Genome Testing
Diagnostic Test
Lead sponsor
Agendia
Industry
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2037
U.S. locations
130
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Jul 22, 2026, 2:08 PM EDT
Active, not recruiting Phase 2 Interventional

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

NCT05456685
View directory record Official record
Conditions
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab soravtansine, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
35
States / cities
Tucson, Arizona • Fresno, California • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

NCT02964585
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3

NCT00789880
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
San Diego, California • Denver, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Not applicable Interventional

Student Anxiety & Stress Study

NCT03986125
View directory record Official record
Conditions
Anxiety, Somatic Symptom Disorder
Interventions
Emotional Awareness & Expression Therapy, Mindfulness Meditation Training
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Jul 22, 2026, 2:08 PM EDT
Completed No phase listed Observational

Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

NCT00897650
View directory record Official record
Conditions
Lung Cancer
Interventions
DNA/RNA sequencing and expression levels, Protein expression analysis, Lung tumor biopsy, Blood sample
Genetic · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Results available

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

NCT01730118
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Adenocarcinomas, Metastatic Solid Tumors Characterized by HER2/Neu Expression
Interventions
Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Jul 22, 2026, 2:08 PM EDT
Recruiting No phase listed Observational

Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

NCT07224880
View directory record Official record
Conditions
glp1 Agonist, Gene Expression, Skin Laxity
Interventions
ellacor
Device
Lead sponsor
Cytrellis Biosystems, Inc.
Industry
Eligibility
30 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dublin, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 22, 2026, 2:08 PM EDT
Recruiting Not applicable Interventional

A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

NCT06127979
View directory record Official record
Conditions
Breast Cancer
Interventions
core needle biopsy, blood draw
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Completed No phase listed Observational

A Study to Identify Differences in Gene Expression in Patients With Bicuspid and Tricuspid Valve Disease

NCT01194362
View directory record Official record
Conditions
Aortic Valve Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Enrolling by invitation No phase listed Observational

RNA Assays for Endometriosis Detection and Diagnosis

NCT06907303
View directory record Official record
Conditions
Endometriosis
Interventions
EndoDx
Diagnostic Test
Lead sponsor
Wren Laboratories LLC
Industry
Eligibility
20 Years to 35 Years · Female only
Enrollment
400 participants
Timeline
2024 – 2026
U.S. locations
1
States / cities
Branford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jul 22, 2026, 2:08 PM EDT
Not listed No phase listed Observational

Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.

NCT00910884
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, therapeutic dietary intervention
Other · Procedure
Lead sponsor
Brabant Research
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Spokane Valley, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 22, 2026, 2:08 PM EDT
Completed No phase listed Observational

Assessment of Insulin Resistance, NAFLD, Predictors of CV Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass Surgery

NCT01007955
View directory record Official record
Conditions
Morbid Obesity, Insulin Resistance, Non-Alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Linagliptin's Effect on CD34+ Stem Cells

NCT02467478
View directory record Official record
Conditions
Type 2 Diabetes, Impaired Renal Function
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Jul 22, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional

Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

NCT03474614
View directory record Official record
Conditions
Cerebral Cavernous Malformations
Interventions
Propranolol, DNA and RNA Analysis
Drug · Genetic
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Jul 22, 2026, 2:08 PM EDT